<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Dividend-Stocks on Archive 03</title><link>https://archive03.online/en/tags/dividend-stocks/</link><description>Recent content in Dividend-Stocks on Archive 03</description><generator>Hugo</generator><language>en</language><lastBuildDate>Thu, 02 Oct 2025 00:00:00 +0000</lastBuildDate><atom:link href="https://archive03.online/en/tags/dividend-stocks/index.xml" rel="self" type="application/rss+xml"/><item><title>Analyzing the $SPHD ETF: Is It Truly Ideal for Monthly Dividend Income Investors?</title><link>https://archive03.online/en/reports/2025-10-02-analyzing-the-sphd/</link><pubDate>Thu, 02 Oct 2025 00:00:00 +0000</pubDate><guid>https://archive03.online/en/reports/2025-10-02-analyzing-the-sphd/</guid><description>We analyze the $SPHD ETF, popular among investors seeking stable cash flow through monthly dividends. While its high dividend yield of over 4% and low volatility are attractive, it has clear limitations like a lack of growth potential and sector concentration. Explore whether SPHD is right for your portfolio through the debate between investors who prioritize stable income over aggressive growth and those who value capital gains.</description></item><item><title>Building a Pension with Dividends? Let's Dive into the $SCHD ETF</title><link>https://archive03.online/en/reports/2025-09-16-building-a-pension/</link><pubDate>Mon, 15 Sep 2025 00:00:00 +0000</pubDate><guid>https://archive03.online/en/reports/2025-09-16-building-a-pension/</guid><description>A deep dive into America&amp;rsquo;s leading dividend growth ETF, $SCHD. Through a debate between Kurumi, who champions its steady cash flow and stability, and Mikael, who points out its growth limitations and interest rate risks, find out if $SCHD is the right fit for your retirement portfolio.</description></item><item><title>Pharma ETF $PPH: A Deep Dive into Its Allure and Pitfalls</title><link>https://archive03.online/en/reports/2025-08-09-pharma-etf-pph/</link><pubDate>Sat, 09 Aug 2025 00:00:00 +0000</pubDate><guid>https://archive03.online/en/reports/2025-08-09-pharma-etf-pph/</guid><description>A deep-dive analysis of the VanEck Pharmaceutical ETF ($PPH). Three characters debate the explosive growth potential of its concentrated strategy, focusing on innovators like Eli Lilly, against the clear pitfalls of high valuation and concentration risk.</description></item><item><title>Coca-Cola ($KO): Is Warren Buffett's 'Golden Goose' Still Viable in 2025?</title><link>https://archive03.online/en/reports/2025-07-18-coca-cola-ko-is/</link><pubDate>Fri, 18 Jul 2025 00:00:00 +0000</pubDate><guid>https://archive03.online/en/reports/2025-07-18-coca-cola-ko-is/</guid><description>From a 2025 perspective, we re-evaluate the investment value of Coca-Cola ($KO), a stock beloved by investing legend Warren Buffett. Through a sharp debate between Kurumi, who champions its stability and brand power backed by 63 years of dividend increases, and Mikael, who points out the risks of stagnant growth and health trends, we analyze the pros and cons of this &amp;lsquo;Dividend King&amp;rsquo;.</description></item></channel></rss>